Baseline Characteristics of Patients Enrolled in PolarisDMD, a Phase 3 Trial of Edasalonexent for Duchenne Muscular Dystrophy

Richard S. Finkel MD1, Craig McDonald MD2, Lee Sweeney PhD4, Kathryn Wagner MD PhD4, Erin Neil DO6, Maria Mancini MHP6, James MacDougall PhD6, Joanne M. Donovan MD PhD6 for the PolarisDMD Investigators

Nemours Children’s Health System, Orlando, FL, 1UC Davis, Sacramento, CA, 2University of Florida, Gainesville, FL, 3Kennedy Krieger Institute, Baltimore, MD, 4University of Michigan, Ann Arbor, MI, 5Catabasis Pharmaceuticals, Boston, MA

Study Design

Activations of NF-kB in Duchenne Muscular Dystrophy is a Key Factor in Disease Progression

Edasalonexent inhibits NF-kB, a Key Driver of Muscle Disease in Duchenne

Edasalonexent Clinical Development Program

Edasalonexent is being developed as a foundational therapy for Duchenne for all patients, regardless of mutation.

Study Design

Background

Study Design

Patients and families

Patient groups

PolarisDMD Phase 3 Site Staff

MoveDMD Phase 2 Site Staff

Catabasis team

Thanks to PPMD and MDA for generous grant support for patient travel in the MoveDMD Phase 2 trial

Questions? Medinfo@catabasis.com

Presented at the 2020 PPMD Annual Conference